UCLA police investigate 2 reports of students drugged at parties
US budget deficit hits $1.8 trillion for fiscal 2024, per CBO
Airlines say they're capping fares in the hurricane's path as Biden warns against price gouging
Musk's X to be reinstated in Brazil after complying with Supreme Court demands
US scrambled to urge Putin not to use nuclear weapons in Ukraine, Woodward book says
Chinese electric carmaker BYD sees EV Mexico sales ramping up to 100,000 in 2025
Jenna Fischer reveals she’s ‘cancer free’ after being diagnosed with breast cancer last year
The challenges Floridians are facing while trying to evacuate
Lindor plays his 1st home game in a month as Mets host Phillies in NLDS
(Reuters) -The U.S. Food and Drug Administration has declined to approve Novo Nordisk's weekly insulin in patients with diabetes, the Danish drugmaker said on Wednesday.
The health regulator in its so-called "complete response letter" sought more information related to the manufacturing process and the type 1 diabetes indication to complete the review, Novo said.
Novo said it does not expect to be able to fulfil the requests this year, and that it will work closely with the FDA regarding the next steps.
The regulator's decision follows its outside panel's vote against the use of the weekly insulin icodec, in patients with type 1 diabetes due to risks of low blood sugar.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
